Prognostic significance of p16INK4a alterations and 9p21 loss of heterozigosity in locally advanced laryngeal squamous cell carcinoma

Journal of Cellular Physiology

Volumn 192, Issue 3, 2002, Pages 286-293

  Bazan, Viviana ^a   Zanna, Ines ^a   Migliavacca, Manuela ^b   Sanz Casla, Maria Teresa ^c   Maestro, Maria Luisa ^d   Corsale, Simona ^d   Macaluso, Marcella ^a   Dardanoni, Gabriella ^a   Restivo, Salvatore ^e   Quintela, Paloma López ^e   Bernaldez, Ricardo ^a   Salerno, Sergio ^a   Morello, Vincenza ^a   Tomasino, Rosa Maria ^a   Gebbia, Nicola ^a   Russo, Antonio ^a,f  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d Epidemiological Observatory Center of Sicilian Region   (Italy)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; DNA; PROTEIN P16;

ADULT; ADVANCED CANCER; AGED; ANEUPLOIDY; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CELL CYCLE; CELL CYCLE S PHASE; CHROMOSOME 9P; DISEASE ASSOCIATION; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; LARYNX CARCINOMA; LARYNX SURGERY; MAJOR CLINICAL STUDY; MALE; METHYLATION; MOLECULAR BIOLOGY; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RELAPSE; SINGLE STRAND CONFORMATION POLYMORPHISM; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; CHEMISTRY; CHROMOSOME 9; DNA METHYLATION; GENETICS; LARYNX TUMOR; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PLOIDY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY;

BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; CHROMOSOMES, HUMAN, PAIR 9; DNA METHYLATION; DNA, NEOPLASM; GENES, P16; HUMANS; LARYNGEAL NEOPLASMS; LOSS OF HETEROZYGOSITY; MULTIVARIATE ANALYSIS; PLOIDIES; POINT MUTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; S PHASE;

EID: 18444395545     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.10138     Document Type: Article

References (52)

1. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization
2. Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas
3. Allele losses in squamous cell carcinomas of the larynx
4. Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer
5. Loss of chromosome arms 3p and 9p and inactivation of p16/INK4a in normal epithelium of patients with primari lung cancer
6. Frequency of homozygous deletion at p16/CDKN2 in primary human tumors
7. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma
8. Hemizygous p16 (INK4A) deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse
9. CDKN2A/p16 is inactivated in most melanoma cell lines
10. An analysis of p16 tumour suppressor gene expression in acral lentiginous melanoma
11. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma
12. Regression models and life tables
13. p16 mutation frequency and clinical correlation in head and neck cancer
14. Homozygous deletion mapping at 9p21 in bladder carcinoma defines a critical region within 2cM of IFNA
15. The prognostic significance of p16INK4a/p14ARF locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia
16. Methylation of the 5′CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing
17. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
18. A common region of homozygous deletion in malignant human gliomas lies between the IFN alpha/omega gene cluster and the D9S171 locus
19. MTS1/CDK4I mutation and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx
20. MTS1/CDK41 protein and mRNA expression is associated with gene alterations in squamous-cell carcinoma of the larynx
21. Loss of heterozygosity at 9p and 17q in human laryngeal tumors
22. Infrequent alterations of the p16INK4a gene in liver cancer
23. Role of the p16 tumor suppressor gene in cancer
24. Structure of the cyclin-dependent kinase inhibitor p19Ink4d
25. 9p21 deletion correlates with recurrence in head and neck cancer
26. INK4a transcript
27. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers
28. Type and number of ki-ras mutations relate to stage of human colorectal cancer
29. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma
30. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
31. Infrequent somatic alteration of p16/MTS1 in human primary superficial bladder cancer
32. The INK4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2′s inhibition of p53
33. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma
34. Loss of heterozygosity at 8p, 9p and 17q in laryngeal cytological specimens
35. The p16INK4a/CDKN2a tumor suppressor and its relatives
36. Vimentin expression, proliferating cell nuclear antigen and flow cytometric factors
37. Flow cytometric DNA analysis and lysosomal cathepsins B and L in locally advanced laryngeal cancer
38. Relationship of ki-ras mutations in colon cancers to tumor location, stage, and survival: A population-based study
39. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
40. Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer
41. Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization
42. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma
43. Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers
44. Prognostic value of the immunohistochemical detection of p16INK4 expression in nonsmall cell lung carcinoma
45. p16INK4A-alterations in primary angiosarcoma of the liver
46. Prognostic significance of cell kinetics in laryngeal squamous cell carcinoma: Clinicopathological associations
47. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas
48. The CDKN2 gene alteration in various types of adult T-cell leukaemia
49. Crystal structure of the CDK4/6 inhibitory protein p18INK4c provides insights into ankyrin-like repeat structure/function and tumor-derived p16INK4 mutations
50. Prognostic impact of INK4a deletion in Ewing sarcoma
51. MTS1/CDK4I is altered in cell lines derived from primary and metastatic oral squamous cell carcinoma
52. Abnormalities of tumor suppressor genes p16 and p15 in primary maxillofacial squamous cell carcinomas